ClinicalTrials.gg
RecruitingNCT06300307ArthemiRUpdated Feb 10, 2026

Study of ATX-01 in Participants With DM1

A Phase 1/2 interventional study of ATX-01 and Placebo in Myotonic Dystrophy 1, sponsored by ARTHEx Biotech S.L.. Recruiting at 12 sites in 7 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by ARTHEx Biotech S.L. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.

Planned enrollment
8th of 22
56 · median 46
Started
2024
with 2 others
Phase 1/2
7 of 43
2 open now
Primary completion
2027-07
later than 8 of 26 live
Registered
30th of 43
by date
Lead sponsor
1 of 43
ARTHEx Biotech S.L.

Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 8th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 1/2, reaches primary completion later than 8 of the 26 other live ones, and was the 30th registered.

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Myotonic Dystrophy with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test ATX-01 in participants with myotonic dystrophy type 1 (DM1). The main question it aims to answer is if ATX-01 is safe and well tolerated. The trial will compare the safety and tolerability of ATX-01 and a matching placebo.

There will be a single-ascending dose part of the trial and a multiple-ascending dose part. In the single-ascending dose, participants will receive one dose of ATX-01 or placebo. In the multiple-ascending dose part, participants will receive three doses of ATX-01 or placebo.

ATX-01 is a novel anti-miR (synthetic single stranded oligonucleotide) that inhibits a microRNA called miR-23b.

03

Conditions studied

  • Myotonic Dystrophy 1

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants with a documented clinical diagnosis of DM1 (CTG expansion of >150 repeats in DMPK gene measured in peripheral blood mononuclear cells)
  • Ambulatory, defined as able to complete a 10-meter walk/run test at screening without the use of assistive devices such as canes, walkers, or orthoses, except for ankle-foot orthoses
  • Presence for >3 seconds of grip myotonia as confirmed by a central reader

Key Exclusion Criteria:

  • Participants with congenital DM1
  • Medical Research Council Muscle Scale score of less than 4 on ankle dorsiflexion or significant tibialis anterior atrophy that prevents a muscle
  • Use of mexiletine or other agent for myotonia within 21 days or 5 half-lives, whichever is longer, prior to screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    ATX-01

    ATX-01 is a formulation of the anti-microRNA 23b (anti-miR-23b), known as X82108, a novel type of antisense oligonucleotide

    Drug: ATX-01

  • Placebo comparator
    Placebo

    Placebo to ATX-01

    Drug: Placebo

Interventions

  • DrugATX-01

    Solution for infusion

  • DrugPlacebo

    Solution for infusion

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    To evaluate the safety and tolerability of ATX-01 in adult participants with DM1

    Time frame: Up to 120 days

Secondary outcomes

  1. Incidence of clinically significant changes in laboratory assessments, electrocardiograms (ECGs), vital signs, suicidal ideation and behavior

    To further evaluate the safety and tolerability of ATX-01 in adult participants with DM1

    Time frame: Up to 120 days

  2. Maximum observed plasma concentration (Cmax) of ATX-01

    Time frame: Up to 48 hours post-dose

  3. Area under the plasma concentration-time curve (AUC) of ATX-01

    Time frame: Up to 48 hours post-dose

  4. Video hand opening time

    To evaluate the efficacy of ATX-01 on myotonia in participants with DM1

    Time frame: Change from baseline up to 120 days

  5. Change from baseline in ankle dorsiflexion strength by quantitative myometry

    To evaluate the effects of ATX-01 in participants with DM1 on ankle dorsiflexion strength

    Time frame: Change from baseline up to 120 days

  6. Change from baseline in Impact on Activities of Daily Living questionnaire item scores

    The Impact on Activities of Daily Living questionnaire is a 7-item patient-reported outcome designed to evaluate the impact of ATX-01 on activities of daily living in participants with DM1.

    Time frame: Change from baseline up to 120 days

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Jul 2027, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2024
First posted
Mar 8, 2024
StartActual
Oct 15, 2024
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06300307
Lead sponsor
ARTHEx Biotech S.L.
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
Oct 15, 2024
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Feb 10, 2026

Study contacts

Project Manager
Contact
clinical@arthexbiotech.com
+34676229821

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion